Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01827943
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:11.611764+00:00
Published At
2021-04-09T00:00:00+00:00
Record Updated At
2021-05-06
Results Posted At
2021-04-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Relapsed Bladder Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-05-06"
protocolSection.identificationModule.nctId
"NCT01827943"
protocolSection.identificationModule.officialTitle
"Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel \u00ae) in Second Line Therapy for Patients With Advanced Bladder Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2021-04-09"

Study condition terms

  • Relapsed Bladder Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.